PRESS RELEASES Manny Suliman 2017-04-27T12:49:25+00:00 Press Releases
- Advaxis Recognized as One of New Jersey’s “Best Places to Work 2017”
- Advaxis Appoints Anthony Lombardo as Chief Business Officer
- Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
- EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer
- Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer
- Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical
- Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO
- Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
- Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
- Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer
- GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer
- New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported
- Advaxis Provides 2017 Business Outlook
